Exclusive Summary

• UB437 is a first-in-class, cell-free, non-exosomal protein complex targeting highly devastating rare neurodegenerative diseases like MSA and CADASIL, for which zero targeted therapies currently exist globally.
• Administered intravenously (IV), it boasts an exceptionally high blood-brain barrier penetration rate (1.17%) for a biologic, circumventing the severe safety and immune rejection risks associated with traditional live-cell therapies.
• The product is currently in the Investigator-Initiated Trial (IIT) stage with active patient enrollment across multiple independent studies, backed by strong preclinical evidence showing potential for cerebral blood flow restoration and remyelination.
• Given the massive unmet medical need and niche disease profile, UB437 is highly positioned to secure FDA/EMA Orphan Drug Designations and accelerated approval pathways, enabling exceptional future pricing power.
• Supported by a standardized, fully industrialized CMC manufacturing process boasting 60%-80% lower COGS than conventional cell therapies, UB437 presents an ideal license-in or co-development asset for global pharma companies building rare CNS portfolios.

Asset Materials

Contact Us for Full Materials